Inspire Medical Systems, Inc. — Q1 2024 10-Q Summary
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. Inspire develops and sells its FDA-approved neurostimulation system for moderate-to-severe obstructive sleep apnea (OSA).
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $164.0 million | $127.9 million | +28.2% |
| Gross profit / margin | $139.3 million / 84.9% | $108.0 million / 84.4% | Margin +0.5 percentage points |
| Operating expenses | $154.5 million | $127.5 million | +21.1% |
| Operating loss | $15.2 million | $19.5 million | Loss narrowed |
| Net loss | $10.0 million | $15.4 million | Loss narrowed 35.1% |
| Basic and diluted loss per share | $0.34 | $0.53 | Loss per share narrowed |
| Operating cash flow | $8.9 million | $(1.3) million | Improved |
Revenue increased in the U.S. by 25.1% to $155.8 million and outside the U.S. by 141.5% to $8.2 million. Management attributed growth to deeper penetration at existing centers, new territories, and greater physician and patient awareness; U.S. growth was partly constrained by ENT surgeon capacity. Gross margin improved primarily because of higher sales volume and manufacturing efficiencies.
Financial position and liquidity
At March 31, 2024, cash and cash equivalents were $175.4 million and short- and long-term investments totaled $293.7 million, for combined cash, cash equivalents, and investments of approximately $469.2 million. Working capital was $500.0 million. Total liabilities were $96.8 million, including $24.5 million of non-current operating lease liabilities; the filing reports no borrowings. The company said existing liquidity and operating cash flows should fund operations and planned capital expenditures for at least the next 12 months.
Investing cash outflow was $19.5 million, including $11.7 million of property and equipment purchases, partly offset by investment maturities and sales. Cash and cash equivalents declined $10.1 million during the quarter. Stock-based compensation was $26.3 million, a significant noncash expense.
Material changes and management commentary
- Operating expenses rose 21.1%, including SG&A growth of 23.2% to $125.6 million, driven mainly by higher employee-related costs, marketing, corporate costs, and travel. R&D increased 13.1% to $28.9 million.
- U.S. commercial reach expanded by 11 sales territories to 298 and by 66 implanting medical centers to 1,246 during the quarter.
- Management expects R&D and SG&A spending to increase further during 2024, as well as additional capital expenditures, primarily for production equipment, the next-generation system, SleepSync, and office improvements. No specific revenue or earnings guidance is provided in the filing.
- Management expects to launch the SleepSync physician programmer in the U.S. in the second half of 2024 and expects EU MDR certification for silicone-based leads in 2024. The next-generation system’s FDA PMA supplement was submitted in June 2023.
Risks, contingencies, and unusual items
- European supply and certification: Delayed EU MDR certification and limited availability of polyurethane-based leads caused European procedure delays and reduced revenue in late 2023. Management estimates a $4.0 million Q4 2023 revenue opportunity impact, some of which it believes was recovered in Q1 2024. Further delays could recur if certification or derogation extensions are not obtained.
- Supply concentration: The company relies on third-party suppliers, many of them single-source, and continues to cite supply-chain and component risks, although constraints eased somewhat.
- Capacity, reimbursement, and competition: ENT surgeon capacity may limit growth. Commercial coverage and reimbursement remain important to adoption. The filing identifies emerging neurostimulation competition and notes that GLP-1 medicines could affect OSA treatment demand; management says any benefit to Inspire from GLP-1 use is uncertain.
- Litigation: An amended securities class-action complaint filed April 19, 2024 alleges that prior disclosures about a customer prior-authorization program violated securities laws. The company intends to defend the case; its outcome and potential financial effect are uncertain.
- Receivables: $1.5 million of accounts receivable was written off, net of recoveries, during the quarter, primarily relating to two healthcare systems. The ending credit-loss allowance was $0.3 million.
- Other considerations: The company remains loss-making, has a $355.4 million accumulated deficit, and reported $0.7 million of income tax expense despite the quarterly loss. Management disclosed uninsured cash balances and sensitivity of interest income to rate changes.
Important facts for investors to verify
- Whether revenue growth and implant-center expansion continue, particularly given ENT capacity constraints and first-quarter seasonality.
- Progress and timing of EU MDR certification, derogations, and European lead supply; assess whether procedure delays recur.
- Whether the planned 2024 spending and capital investment increases are matched by revenue growth and improved operating performance.
- Developments in the securities class action, reimbursement coverage, and competing OSA therapies, including GLP-1 treatments.
- Cash conversion, inventory growth and obsolescence exposure, and the size and impact of stock-based compensation.